

COMMENTARY

Treating endometriosis with the levonorgestrel-releasing intrauterine system: real hope or gimmick?

Mofid Ibraheim, Amaju Ikomi

Background

Endometriosis is a condition that significantly affects the quality of life of approximately 10–15% of women in their reproductive years and yet treatment remains problematic.¹ Drug treatment, which is predominantly palliative, for symptoms of dysmenorrhoea, dyspareunia, non-cyclical pelvic pain and/or menorrhagia is hormonally based. Amongst the therapeutic options are anti-oestrogens (e.g. danazol) and regimens that induce either a medical menopause (e.g. GnRh agonists) or a pseudo-pregnant state (e.g. continuous combined oral contraceptives or high-dose progestogens).² Although these drugs are effective in the short term, due to expense and concerns about their long-term safety, some of them (e.g. GnRh agonists) should be withdrawn after a few months. Also, systemic side effects commonly affect compliance; the need for regular administration may further result in poor compliance, which undermines efficacy.

Another problem is the fact that even after successful treatment of endometriosis, symptom recurrence is common. It is reported that the cumulative recurrence rates for the fifth year following successful medical treatment are 37% for minimal disease and 74% for severe disease.³ Laparoscopic ablation or excision is usually effective, but even with this treatment modality, relapse is common.⁴

It is highly regrettable that there remains a paucity of established, simple and cost-effective drug regimens that can be used safely in the long term to control the symptoms of pelvic endometriosis. The development of drugs administered locally to the pelvic organs could limit the metabolic impact without detracting from efficacy and therein may lay the answer to the long-term therapeutic void.

Benefits of the LNG-IUS

The levonorgestrel-releasing intrauterine system (LNG-IUS) Mirena® provides an alternative means of administering progestogens. It was developed as a contraceptive device and releases levonorgestrel to the endometrium at a low rate of 20 µg/24 hours, and its effectiveness lasts 5 years. The progestogen induces endometrial atrophy with minimal systemic side effects due to limited diffusion of the hormone beyond the uterus. This results in a significant reduction in menstrual blood loss and associated dysmenorrhoea in menorrhagic women.⁵ The device is now licensed in the UK as a treatment for menorrhagia. Similar beneficial effects have been demonstrated in menorrhagic women with uterine pathology such as fibroids⁶ and adenomyosis.⁷

As far back as 10 years ago, Singer and Ikomi⁸ reported anecdotal cases of symptomatic relief in endometriosis patients using the LNG-IUS whilst awaiting laparoscopic surgery. It has taken some time but there are now a few published studies indicating a role for this device in treating endometriosis. In a small, prospective, non-comparative, pilot study, Vercellini *et al.*⁹ monitored the effect of the LNG-IUS on 20 parous women with recurrent moderate or severe dysmenorrhoea after conservative surgery for endometriosis in the previous 12 months. Subjects were eligible if they had at least moderate pain on visual analogue and verbal rating scales and a normal uterus and adnexae at clinical examination and transvaginal ultrasonography. At 12-month follow-up there was a highly significant reduction (>50%) in menstrual pain and this was associated with a high degree of patient satisfaction. The small sample size, the relatively short follow-up period and a failure to evaluate the effect on other symptoms such as dyspareunia and non-menstrual pain undoubtedly limited the strength of this pilot study, but provided a clear indication of the potential of the device in treating this condition.

A further study by Fedele *et al.*¹⁰ evaluated the effectiveness of the LNG-IUS as therapy in eleven symptomatic patients with rectovaginal endometriosis over 12 months. In this prospective, therapeutic, non-randomised study all the patients had been diagnosed with pelvic endometriosis and had been surgically treated by laparotomy or laparoscopy in the 12 months before enrolment. Deep endometriosis involving the rectovaginal septum had not been treated. The study demonstrated a great improvement in dysmenorrhoea, non-menstrual pelvic pain and dyspareunia, as well as a reduction in the ultrasonographic dimensions of the rectovaginal nodules. These findings reinforced those of the earlier study⁹ and provided the first indication of a potential cytreductive effect on the endometriotic lesions.

This concept of a potential cytreductive effect was explored in a recent prospective, non-comparative study of 34 women with clinically suspected and laparoscopically confirmed symptomatic minimal to moderate endometriosis.¹ In this study by Lockhat *et al.*¹¹ the severity of pelvic pain was scored using the visual analogue scale and the severity of pelvic pain (dysmenorrhoea and/or non-cyclical pelvic pain) was rated on a four-point verbal rating scale. All the subjects underwent a standard two-port diagnostic laparoscopy to confirm the diagnosis of endometriosis with video documentation prior to insertion of the IUS. After 6 months, 29 women remained in the study and five discontinued, for personal reasons (one), side effects of worsening acne (two) and lower abdominal/pelvic pain (three). Second-look laparoscopy was performed again on 26/29 of these women, with video documentation. There was a statistically significant improvement in the severity and frequency of pain as well as the staging of the disease. Peritoneal endometriotic lesions mainly appeared to respond, while the presence of adhesions was not altered. However, an improvement in symptoms was not necessarily associated with changes in the staging, a finding that is in keeping with the enigmatic nature of this condition.

J Fam Plann Reprod Health Care 2005; **31**(3): 182–184

Department of Obstetrics and Gynaecology, Basildon University Hospital, Basildon, UK

Mofid Ibraheim, MRCOG, DFFP, *Specialist Registrar*
Amaju Ikomi, MRCOG, *Consultant and Clinical Lead for Research and Development*

Correspondence to: Mr M Ibraheim, Department of Obstetrics and Gynaecology, Basildon University Hospital, Nethermayne, Basildon, Essex SS16 5NL, UK.
E-mail: mofidibraheim@yahoo.co.uk

Long-term treatment options

Lockhat *et al.*¹¹ have recently published an update on the progress of women in the previous study that provides good evidence of longer-term therapeutic effect with the LNG-IUS. The women were followed up every 6 months for up to 3 years. The LNG-IUS continuation rates were 85%, 68%, 62% and 56% at 6, 12, 24 and 36 months, respectively. Overall, significant improvements in pain and menstrual loss scores were observed throughout the 36 months. The 56% continuation rate at 3 years was very reassuring and similar to that in previous studies of the LNG-IUS as a treatment for menorrhagia.¹² On the basis of this study, one should anticipate effective long-term symptom control in those patients who report an initial improvement in symptoms with the IUS *in situ*: an indication of its strong potential to fill the long-term therapeutic void to which we have previously alluded.

Ideally, the true worth of the LNG-IUS as a single primary treatment for endometriosis should be clarified by randomised controlled trials (RCTs), but unfortunately there are limiting factors. For example, it would be unethical to perform placebo comparison studies in symptomatic patients and double blinding would be most challenging in any direct comparisons with established primary treatment modalities. Nonetheless, the only published RCT to date¹³ provides highly encouraging evidence in support of a role for the LNG-IUS as an adjunct to primary treatment by conservative surgery. This open-label, parallel-group RCT compared immediate treatment with the LNG-IUS with expectant management after operative laparoscopy for symptomatic endometriosis. Forty women were recruited and randomised equally into both treatment groups. One year after surgery the median dysmenorrhoea scores were significantly lower in the IUS group compared to the expectant management group. Also, the incidence of significant dysmenorrhoea was lower in the LNG-IUS group (10% vs. 45%). The absolute risk reduction equates to prevention of recurrent dysmenorrhoea in one out of three patients, 1 year after surgery.

This demonstration of a reduction in medium-term risk of recurrent symptoms is highly important, considering previous reports of high relapse rates following initial successful treatment. Also, these data reinforce the potential of the IUS as a long-term treatment option and raise the possibility of a protective effect from the complications of endometriosis in long-term contraceptive users of the IUS. A protective effect from the complications of fibroids has already been reported.¹⁴

Mechanisms of action

What are the possible mechanisms of a beneficial effect of the LNG-IUS on endometriosis?¹ Its influence on menstrual pain can be explained either by reduced uterine spasm simply due to IUS-induced hypomenorrhoea or by a more complex effect on the now recognised paracrine activity of the endometrium. Prostaglandin $F_{2\alpha}$ is produced in secretory endometrium and is thought to be the main agent responsible for dysmenorrhoea by stimulating uterine contractions in the non-pregnant uterus.¹⁵ The IUS causes a decrease in endometrial proliferation and an increase in apoptosis in endometrial glands and stroma.¹⁶ The resultant atrophy leads to an altered expression of many locally acting mediators¹⁷ including vascular growth factors and prostaglandins, thus potentially affecting vascularity and uterine spasm/pain. An effect on non-menstrual pain, dyspareunia and cyto-reduction of the lesions is more difficult to explain. It has been suggested that this could be due to a receptor-mediated action of locally released levonorgestrel on deep endometriotic foci

adjacent to the isthmus and uterine cervix.¹³ This hypothesis is supported by an even more recent study by Lockhat *et al.*¹⁸ in which serum and peritoneal fluid levels of levonorgestrel were quantified in endometriosis sufferers 6 months after insertion of the IUS. In patients showing an improvement in symptoms they demonstrated a significant delivery of levonorgestrel to peritoneal fluid with levels approximating two-thirds of the serum levels, and showed that a linear relationship exists between levonorgestrel levels in these compartments. Other possibilities include theories about alterations in uterine blood flow or disruption of follicular activity.¹

Conclusions

Whilst the mechanisms remain open to question, it has become increasingly difficult to ignore the apparent and consistent effectiveness of the IUS in providing relief in a large proportion of patients with pain and menstrual disorder associated with endometriosis. Indeed, the current evidence has led many gynaecologists to include this device in their therapeutic armamentarium for endometriosis. Nevertheless, it is a fact that some questions remain unanswered and larger controlled trials are needed. Future research also needs to focus on the relative effectiveness of this device compared to other established medical options and to further clarify its effect on non-menstrual pain and dyspareunia.

On the basis of the available evidence, the LNG-IUS appears to be a very reasonable option for endometriosis patients with predominantly menstrual symptoms, especially if they also have contraceptive needs. With a monthly cost over 5 years of only £1.49, this is an option all practitioners must be prepared to consider for their patients. In our opinion, the resounding verdict is one of real hope. Treating endometriosis sufferers with the LNG-IUS is no gimmick.


Statements on funding and competing interests

Funding. None identified.

Competing interests. None identified.

References

- Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. *Hum Reprod* 2004; **19**: 179–184.
- Morghissi K. Medical treatment of endometriosis. *Clin Obstet Gynaecol* 1999; **42**: 620–632.
- Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. *Cochrane Database Syst Rev* 1997; **4**: CD001019
- Vercellini P, De Giorgi O, Pisacreta A, Pesole AP, Vicentini S, Crosignani PG. Surgical management of endometriosis. *Baillieres Clin Obstet Gynaecol* 2000; **14**: 501–523.
- Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device and norethisterone in the treatment of menorrhagia. *Br J Obstet Gynaecol* 1990; **97**: 690–694.
- Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. *Fertil Steril* 2003; **79**: 1194–1198.
- Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. *Fertil Steril* 1997; **68**: 426–429.
- Singer A, Ikomi A. Intrauterine progesterone: a new approach to treating endometriosis? *Gynaecol Endosc* 1995; **4**: 39.
- Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhoea associated with endometriosis: a pilot study. *Fertil Steril* 1999; **72**: 505–508.
- Fedele L, Bianchi S, Zanonoto G, Portuese A, Ricciardia R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. *Fertil Steril* 2001; **75**: 485–488.
- Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis



COMMENTARY/FACULTY EXAMINATIONS

- undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. *Hum Reprod* 2005; **20**: 789–793.
- 12 Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, *et al.* Open randomised study of use of levonorgestrel releasing system as alternative to hysterectomy [with a commentary by A Prentice]. *BMJ* 1998; **316**: 1122–1126.
 - 13 Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. *Fertil Steril* 2003; **80**: 305–309.
 - 14 Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mcg/d and the Copper TCU 380 Ag intrauterine contraceptive devices: a multicenter study. *Fertil Steril* 1994; **61**: 70–77.
 - 15 Lumsden MA, Kelly RW, Baird DT. Primary dysmenorrhoea: the importance of both prostaglandins E2 and F2 alpha. *Br J Obstet Gynaecol* 1983; **90**: 1135–1140.
 - 16 Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. *Hum Reprod* 2001; **16**: 2103–2108.
 - 17 Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. *Hum Reprod* 2000; **15**: 162–172.
 - 18 Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. *Fertil Steril* 2005; **83**: 398–404.

MEMBERSHIP OF THE FACULTY OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE

The MFFP Examination consists of:

Part 1 (A or B) New format Multiple Choice Question paper (MCQ)

Part 1A Examination: For those who have not passed the Part 1 MRCOG nor received exemption from Part 1 MRCOG. This 2-hour paper consists of 60 MCQs based on basic, applied and clinical science.

Part 1B Examination: For those who have passed the Part 1 MRCOG or have received exemption from Part 1 MRCOG and wish to be exempt from the basic science component of the Part 1A. This 1½-hour paper consists of 45 MCQs based on clinical and applied science.

Part 1 (A and B) examinations will be held on **Tuesday 25 April 2006** (applications must be received by **1 January 2006**). The examinations will also be held in October 2006 – the date is yet to be confirmed.

Part 2 Examination (Dissertation or Case Reports)

Part 2 - Dissertation or Case Reports

Submission of one Dissertation (10 000 words) or two Case Reports (2500 ± 500 words each).

Approval of the Dissertation or Case Reports titles by the Dissertation/Case Reports Convenor **must be obtained before** the candidate starts work on the Dissertation or Case Reports **and before** the candidate applies to sit the Part 2 (CRQ, MEQ, OSCE) component. Guidance notes and proposal form, plus exemption form/information, are available on request (see below).

Part 2 Examination (CRQ, MEQ, OSCE)

Part 2 – CRQ, MEQ, OSCE

Critical Reading Question examination paper (**CRQ**)

Modified Essay Question examination paper (**MEQ**)

Objective Structured Clinical Examination (**OSCE**)

Applications for the **Part 2** held in **June 2006** must be received by **1 December 2005**.

Please consult the revised Examination regulations for changes to entry requirements.

The qualification is subject to re-certification every 5 years.

Revised regulations (June 2004), application forms and dissertation documents are available on application to: Miss Denise Newell, Examination Secretary, Faculty of Family Planning and Reproductive Health Care of the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Tel: +44 (0) 20 7724 5629. Fax: +44 (0) 20 7723 5333. E-mail: denise@ffprhc.org.uk. Website: www.ffprhc.org.uk

